News
SLDB
4.910
+4.91%
0.230
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
Benzinga · 8h ago
Solid Biosciences Initiated at Outperform by Wedbush
Dow Jones · 16h ago
Solid Biosciences Price Target Announced at $16.00/Share by Wedbush
Dow Jones · 16h ago
Wedbush Initiates Coverage On Solid Biosciences with Outperform Rating, Announces Price Target of $16
Benzinga · 17h ago
Wedbush starts Solid Biosciences at Outperform on ‘potentially better’ DMD tool
TipRanks · 1d ago
Solid Biosciences initiated with an Outperform at Wedbush
TipRanks · 1d ago
Solid Biosciences Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
Promising Outlook for Solid Biosciences’ SGT-003 Therapy Boosts Buy Rating
TipRanks · 1d ago
HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target
Benzinga · 1d ago
Solid Biosciences Price Target Announced at $15.00/Share by JMP Securities
Dow Jones · 3d ago
JMP Securities Initiates Coverage On Solid Biosciences with Market Outperform Rating, Announces Price Target of $15
Benzinga · 3d ago
Solid Biosciences initiated with an Outperform at JMP Securities
TipRanks · 3d ago
Buy Rating Affirmed: Solid Biosciences’ Strong Potential in Gene Therapy for DMD Highlighted by Innovative Technologies and Attractive Valuation
TipRanks · 3d ago
Weekly Report: what happened at SLDB last week (1202-1206)?
Weekly Report · 4d ago
Solid Biosciences management to meet with Piper Sandler
TipRanks · 12/06 18:25
Strategic Collaboration with Mayo Clinic Boosts Solid Biosciences’ Buy Rating for Cardiac Gene Therapy Advancements
TipRanks · 12/06 05:59
Analysts Conflicted on These Healthcare Names: Solid Biosciences (SLDB), Foghorn Therapeutics (FHTX) and KalVista Pharmaceuticals (KALV)
TipRanks · 12/05 18:30
Insider Sale: President and CEO of $SLDB (SLDB) Sells 11,114 Shares
Barchart · 12/05 02:40
Insider Sale: Chief Technology Officer of $SLDB (SLDB) Sells 2,777 Shares
Barchart · 12/05 01:52
Solid Biosciences announces collaboration with Mayo Clinic
TipRanks · 12/04 13:16
More
Webull provides a variety of real-time SLDB stock news. You can receive the latest news about Solid Bioscience through multiple platforms. This information may help you make smarter investment decisions.
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.